Study Comparing Treatment With Alluzience vs Reconstituted Toxin
- Conditions
- Glabellar Frown Lines
- Interventions
- Biological: AlluzienceBiological: powder BoNT-A (BOTOX/Vistabel)
- Registration Number
- NCT05277337
- Lead Sponsor
- Galderma R&D
- Brief Summary
This is a Phase IV, open-label, randomized, interventional, two-armed, multi-centre study to investigate subject treatment perception and Investigator treatment experience when using Alluzience or vacuum-dried botulinum neurotoxin type A (powder BoNT-A) for treatment of glabellar lines (GL).
- Detailed Description
This is a Phase IV, open-label, randomized, interventional, two-armed, multi-centre study to investigate subject treatment perception and Investigator treatment experience when using Alluzience or vacuum-dried botulinum neurotoxin type A (powder BoNT-A) for treatment of glabellar lines (GL).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 150
- Female 18 to < 65 years of age.
- Moderate to severe GL at maximum frown as assessed by the Investigator.
- Female of non-childbearing potential (i.e., postmenopausal [absence of menstrual bleeding for 1 year prior to screening, without any other medical reason], or has undergone hysterectomy or bilateral oophorectomy). OR Female of childbearing potential with a negative urine pregnancy test at screening and baseline, and agrees to use a highly effective and approved contraceptive method for the duration of the study.
- Time and ability to complete the study and comply with instructions.
- Understands the study requirements and signed the informed consent form (ICF).
- Subjects who have planned to undergo aesthetic facial treatment with powder toxin at the study site.
- Previous use of any approved botulinum toxin in facial areas.
- Previous use of any botulinum toxin in facial area within 6 months prior to study treatment.
- Female who is pregnant, breast feeding, or intends to conceive a child during the study.
- Known allergy or hypersensitivity to any component of the study product or any botulinum toxin serotype.
- Any known contraindication such as subject with bleeding disorder or subject currently using anticoagulants.
- Previous use of any hyaluronic acid soft tissue augmentation therapy in the treated area within 3 months before baseline.
- Previous soft tissue augmentation with any permanent (non-biodegradable such as silicone, polyacrylamide, etc) or semi-permanent (i.e., calcium hydroxylapatite, poly-L-Lactic acid or polymethyl-methacrylate) product; lifting threads, or autologous fat in the treatment area.
- Subject has any prior or current psychiatric illness (e.g. Psychosis, depression, anxiety), alcohol or drug abuse, or is taking antidepressant, anxiolytic, or antipsychotic medication that, in the Investigator's opinion, could affect the subject's safety and/or participation in the study.
- Other concurrent medical conditions, therapy, or other condition that, in the Investigator's opinion, would interfere with the evaluation of the study medication, safety or efficacy, and/or put the subject at risk if he/she participates in the study.
- Participation in an investigational device or drug study within 30 days prior to study treatment or plans to enroll in any other investigational study during participation in this study.
- Study site personnel, close relatives of the study site personnel (e.g. parents, children, siblings, or spouse), employees or close relatives of employees at the Sponsor company.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group 1 (Alluzience) Alluzience Single treatment at the baseline visit with Alluzience. Glabellar lines will be treated with 10 U/0.05 mL per injection point. In total 50 s.U in 0.25 mL for 5 injection points. Group 2 (powder BoNT-A: BOTOX/Vistabel) powder BoNT-A (BOTOX/Vistabel) Single treatment at the baseline visit with powder BoNT-A (BOTOX/Vistabel). Glabellar lines will be treated with 4 U/0.1 mL per injection point. In total 20 U in 0.5 mL for 5 injection points.
- Primary Outcome Measures
Name Time Method Time Needed to Prepare Alluzience and Powder BoNT A Baseline (Day 0) Time to prepare Alluzience and powder Bont A according to protocol was reported.
- Secondary Outcome Measures
Name Time Method Investigator Treatment Session Questionnaire Baseline (Day 0) Treating investigators who injected participant with Alluzience answered questions 1 through 12 of the investigator treatment questionnaire for each participant at baseline. The options for each question were strongly agree, agree, neither agree nor disagree, disagree and strongly disagree.
Percentage of Participants Injected With Alluzience for Whom Investigator Did Not Face Technical Issue/Problems When Using a Ready-to-use Product as Compared to a Product to be Reconstituted Baseline (Day 0) Percentage of participants injected with Alluzience for whom investigator did not face technical issue/problems when using a ready-to-use product as compared to a product to be reconstituted, assessed using answers within each answer option (strongly agree, agree, neither agree nor disagree, disagree and strongly disagree) was reported.
Percentage of Participants Injected With Powder Bont-A for Whom Investigator Experienced Issues While Reconstitution Baseline (Day 0) Percentage of participants injected with Powder Bont-A for whom investigator experienced issues while reconstitution was assessed using a questionnaire (Yes/No). Percentage of participants with answer "Yes" was reported.
Trial Locations
- Locations (8)
Galderma Research Site 1004
🇬🇧London, United Kingdom
Galderma Research Site 1006
🇬🇧London, United Kingdom
Galderma Research Site 2003
🇩🇪Bochum, Germany
Galderma Research Site 1001
🇬🇧London, United Kingdom
Galderma Research Site 1003
🇬🇧Edinburgh, United Kingdom
Galderma Research Site 2002
🇩🇪Düsseldorf, Germany
Galderma Research Site 1002
🇬🇧Street, United Kingdom
Galderma Research Site 2001
🇩🇪Düsseldorf, Germany